Biosensor Recession proof -heartstent biz

Nosges Bank bought 1.379m Biosensors share at $1.26 and increase holding from 4.96% to 5.04%.

Biosensors continues to be greatly undervalued despite going up 1.5 cents to $1.25 currently. Good luck ,,

Biosensors potential takeover target.

 
Worth at least a small bet at this price level of 1.115.
Strong potential ahead.

Incredible value at now $1.055

Some funds are selling for a reason that has been around quite a while, so it's not new, and it's  mandatory stent price cuts directed by authorities in Japan,  India & China.

Yes you can see how things have hit Terumo Corp (Terumo), which licenses BIG’s drug-eluting stent technology in exchange for a royalty fee.

In results on Tuesday,  you can see its  drug eluting stent sales in Japan was felled by the National Health Insurance’s  official price cut (~15%) and increased competition from new product launches.